From Signal Detection to Evaluation to Action: The experience of Pediacel® and Apnea

Oct-11

AUTHORS : Alena Khromava, Epidemiology and Benefit Risk, Sanofi Pasteur, 1755 Steeles AvenueWest, North York, Ontario M2R 3T4, Canada – Email: Alena.Khromava@sanofi.com

JOURNAL : Drug Safety

REFERENCE: 34(10):910-11

DOI : 10.2165/11596230-000000000-00000

From Signal Detection to Evaluation to Action: The experience of Pediacel® and Apnea

More publications

Comparative effect of aspirin versus clopidogrel monotherapy on incident type 2 diabetes in patients with atherosclerotic cardiovascular diseases: A target trial emulation study

Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement

Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study